Immunovant (IMVT) Return on Invested Capital (2019 - 2023)

Immunovant's Return on Invested Capital history runs 5 years deep, the most recent figure standing at 20.31% for Q4 2023.

• Quarterly Return on Invested Capital rose 2504.0% year-over-year to 20.31% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 20.31% (up 2504.0% YoY) and the FY2023 annual result came in at 4.57%, changed N/A from the prior year.
• Return on Invested Capital was 20.31% for Q4 2023 at Immunovant, up from 11.04% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 20.31% in Q4 2023 and bottomed at 10.1% in Q3 2022.
• A 5-year average of 0.37% and a median of 0.1% in 2020 frame the typical range for Return on Invested Capital.
• Annual changes were most pronounced in 2022 — Return on Invested Capital plunged 1014 bps — and 2023, when it jumped 2504 bps.
• Immunovant's Return on Invested Capital stood at 0.02% in 2019, then soared by 618 bps to 0.17% in 2020, then jumped by 282 bps to 0.64% in 2021, then slumped by 836 bps to 4.74% in 2022, then soared by 529 bps to 20.31% in 2023.
• Business Quant data shows IMVT's Return on Invested Capital at 20.31% in Q4 2023, 11.04% in Q3 2023, and 0.24% in Q2 2023.